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Citrate therapy for polycystic kidney disease in rats. autosomal dominant PKD, the Han:SPRD strain, in a
Background. Few treatments are available to slow the pro- laboratory animal-breeding facility in Hanover, Ger-
gression to renal failure in autosomal dominant polycystic kid- many [2]. Homozygous animals with altered PKD genesney disease (PKD). In an animal model of PKD, the male
develop massively enlarged cystic kidneys and die atheterozygous Han:SPRD rat, intake of a solution of potassium
about three to four weeks of age. Heterozygous malescitrate plus citric acid (KCitr) from age one to three months
prevented a decline in glomerular filtration rate (GFR). The and females develop a slowly progressive cystic disease,
present study tested whether this beneficial effect is sustained which is much more severe in males than in females.
and explored handling of citrate and ammonia in normal and Death from renal failure in male heterozygotes occurscystic kidneys.
at a median age of about 6 [2] or 17 months [3] in differentMethods. Rats were provided with tap water or citrate solu-
colonies. The heterozygous Han:SPRD rat with PKDtions to drink, and clearance and survival studies were performed.
Results. The GFRs of rats with PKD that consumed KCitr may be a useful model for human autosomal dominant
from one month of age were normal at six months of age, while PKD [2–5], even though the abnormal gene in the rat
those of their counterparts on water were about one third of
[6] may not correspond to the PKD-1 or PKD-2 genesnormal. Long-term KCitr treatment extended the average life
that are defective in almost all patients with ADPKD.span of rats with PKD from 10 to 17 months. Compared with
normal rats, water-drinking rats with PKD had higher plasma We recently demonstrated that if heterozygous male
[citrate], renal cortical [citrate], and fractional excretion of Han:SPRD rats with PKD were provided with a solution
citrate, and lower rates of renal citrate consumption, ammonia of potassium citrate/citric acid (abbreviated “KCitr”) to
synthesis, and ammonia excretion. Cortical PNH3 was not elevated drink, starting at one month of age, then the glomerularin cystic kidneys. Intake of Na3 citrate/citric acid solution or K3
filtration rate (GFR) was sustained at a normal level andcitrate solution, but not ammonium citrate/citric acid solution,
prevented a decline in GFR in three-month-old rats with PKD. the kidneys showed less cystic disease when the rats were
Conclusions. Rats with PKD show abnormal renal handling three months old [7]. By contrast, littermate rats with
of citrate and ammonia. Citrate salts that have an alkalinizing PKD that drank tap water had a GFR one half of normal,effect preserve GFR and extend survival.
large kidney cysts, and extensive renal interstitial dis-
ease. The present study had two purposes: (1) to ascer-
tain whether the benefits of KCitr therapy would beAutosomal dominant polycystic kidney disease
sustained beyond three months, and (2) to examine the(ADPKD) is an inherited disorder that afflicts more than
mechanism of this beneficial effect.500,000 people in the United States alone and millions
To assess the effectiveness of KCitr administrationmore worldwide. This disease is accompanied by the for-
beyond three months of age, we treated Han:SPRD ratsmation and enlargement of numerous fluid-filled epithelial
with KCitr for longer times in two sets of experiments.sacs (cysts) in both kidneys and eventual development
First, we treated rats, starting at the age of one month,of renal failure. There is currently no specific treatment
and measured renal function at six months of age. Sec-to halt or slow the progression of renal failure in patients
ond, we treated rats from the age of one month until theirwith PKD [1].
deaths to see whether this treatment prolonged survival.In 1991, Kaspareit-Rittinghausen, Deerberg, and Wcislo
To gain some insight into the mechanism of KCitrdiscovered a mutant strain of Sprague-Dawley rats with
therapy, we examined several parameters. First, we mea-
sured blood and urine pH values to determine whether
KCitr intake affected these variables. Second, we hy-Key words: autosomal dominant polycystic kidney disease, potassium
citrate, sodium citrate, citric acid, renal ammonia, Han:SPRD rat. pothesized that renal citrate handling might be abnormal
in rats with PKD, based on a previous report that citrateReceived for publication October 19, 1999
excretion is abnormally elevated in these rats [8]. Weand in revised form May 12, 2000
Accepted for publication May 19, 2000 therefore measured plasma and renal tissue citrate levels
and renal reabsorption and consumption of citrate; theÓ 2000 by the International Society of Nephrology
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effects of KCitr treatment on these parameters were also of a solution containing 3% polyfructosan (Laevosan Co.,
Linz, Austria), 5.5 to 11 mg/mL sodium p-aminohippuratestudied. Third, since Torres et al had suggested that
(PAH), 2 g/100 mL bovine serum albumin, 24 mmol/Lincreased ammonia levels contribute to damage in cystic
NaHCO3, and 125 mmol/L NaCl. A femoral artery waskidneys, we determined renal cortical tissue PNH3 and
cannulated for blood sampling and for measuring bloodammonia production and excretion [9, 10]. Fourth, we
pressure with a transducer (Gould-Statham, Hato Rey,tested the idea that KCitr’s beneficial effect is dependent
Puerto Rico). The abdomen was opened via a midlineon the well-known interaction between citrate and cal-
incision. The left ureter was cannulated, and a cannulacium ions in the body [11]. Finally, we substituted ammo-
was inserted into the bladder to drain urine from thenium or sodium ions for potassium ions in the citrate
right kidney. A number 25 needle, connected to a shortsolution and also gave K3 citrate (tripotassium citrate
length of Silastic tubing, was inserted into the left renalwithout citric acid) to determine whether the beneficial
vein for blood sampling.effect of the KCitr solution was related to its potassium
Renal clearance measurements were made as follows:content or to its alkalinizing effect.
About one hour after the left ureter had been cannu-
lated, we collected two 30-minute urine samples under
METHODS water-equilibrated light mineral oil. Urine volume was
determined by weighing, assuming a density of one. UrineAnimals and solutions
pH was measured immediately at room temperature us-All experiments were conducted in accordance with
ing a 9802BN micro-pH combination electrode (Orionthe National Institutes of Health Guide for the Care and
Research, Beverly, MA, USA). Arterial and renal venousUse of Laboratory Animals. Experiments were per-
blood samples (0.60 to 0.85 mL) were collected at theformed on heterozygous male Han:SPRD rats with PKD
beginning and end of the urine collections. When deter-and their normal littermates. The breeding stock was
minations of plasma ammonia levels were made, bloodobtained from the Polycystic Kidney Program at the
samples were collected in iced syringes. Plasma andUniversity of Kansas. All animals were allowed free ac-
blood cells were separated immediately. Plasma proteinscess to a diet containing 24% protein and 6% fat (Teklad
were precipitated with iced 10% trichloroacetic acid.6% mouse/rat diet 7002; Harlan, Madison, WI, USA).
Supernatants were frozen, and analyses were completedIn most experiments, rats were provided with either a
within a few hours. An arterial blood sample (0.25 mL)solution of 55 mmol/L tripotassium citrate/67 mmol/L
was also collected anaerobically for measurement of bloodcitric acid (KCitr) or tap water to drink beginning at one
gases and pH using an IRMA series 2000 blood systemmonth of age, and they were studied at six months of
(Diametrics Medical, St. Paul, MN, USA) or model 1400
age or long-term survival was followed. In other experi- blood gas electrolyte analyzer (Instrumentation Labora-
ments, normal rats or rats with PKD were provided with tories, Lexington, MA, USA). In some experiments, a
solutions of either (1) 82.5 mmol/L diammonium citrate/ terminal blood sample (0.25 mL) was collected for
39.5 mmol/L citric acid, (2) 55 mmol/L trisodium sodium plasma calcium and phosphate determinations.
citrate/67 mmol/L citric acid, or (3) 55 mmol/L K3 citrate The clearance studies in three-month-old rats were
to drink from one month of age, and they were studied done in exactly the same way as in our previous study
at three months of age. The milliequivalents of citrate on rats of this age [7].
in all citrate solutions were the same. Drinking solutions
were made up in tap water. Long-term survival
Survival studies were performed on 18 male heterozy-Clearance studies
gous rats with PKD that drank water and on six male
Before experiments, six-month-old rats were deprived heterozygous rats that drank KCitr solution starting at
overnight of food but had free access to water or citrate one month of age. Three normal rats on KCitr intake since
solution. They were intraperitoneally anesthetized with one month of age were sacrificed when 21 months old.
the thiobarbiturate Inactin (130 mg/kg body weight; Byk
Tissue collectionGulden, Konstanz, Germany). Each animal was placed
on a heated table, and rectal temperature (monitored At the end of most clearance experiments, one kidney
with a probe) was kept at 378C. The trachea was cannu- (usually the left) was rapidly removed. Cortex and me-
lated, and a slow flow of moistened 35% O2/65% N2 was dulla were separated, and wet and dry weights (samples
passed over the opening of the cannula. A femoral vein heated in an oven at 1208C for 16 hours) were deter-
was cannulated for infusions. One milliliter of 6 g/100 mL mined. In other experiments, samples for tissue calcium
fraction V bovine serum albumin in 0.9% NaCl was ad- were obtained after separating kidney cortex and me-
ministered intravenously during the surgical preparation. dulla. Samples for tissue citrate were obtained by rapidly
This was followed by a priming dose (0.2 mL/100 g body slicing off a piece of cortex, freeze-clamping it in liquid
nitrogen, and then homogenizing the sample in iced 10%weight) and constant intravenous infusion at 3 mL/hour
Tanner and Tanner: Citrate treatment in PKD rats 1861
perchloric acid. The samples were centrifuged, and the Calculations
supernatants were then filtered through a 10,000 molecu- The GFR was calculated from the rate of excretion
lar weight cutoff UltraFuge filter (Micron Separations, of polyfructosan divided by the plasma polyfructosan
Westboro, MA, USA). concentration. Renal plasma flow (RPF) was calculated
from the PAH clearance divided by the PAH extractionHistology
ratio ((arterial minus renal venous plasma [PAH]) 4
The remaining kidney was fixed by retrograde aortic arterial plasma [PAH]). Renal blood flow (RBF) was
perfusion with a solution of 3% paraformaldehyde, 137 calculated from this formula: RBF 5 RPF/(1 2 hemato-
mmol/L NaCl, 2.7 mmol/L KCl, 1.5 mmol/L KH2PO4, 4 crit). Renal citrate consumption was calculated from
mmol/L Na2HPO4, and 2 mmol/L picric acid. at a perfu- RPF 3 (arterial plasma [citrate] 2 renal vein plasma
sion pressure of 150 to 170 mm Hg. The kidney was [citrate]) minus urinary citrate excretion rate. Tubular
kept in the same fixative solution for several days in the reabsorption was calculated from the filtered load minus
refrigerator and then weighed, sliced with a razor blade, the excretion rate. Peritubular uptake of citrate was cal-
immersed in 0.1 mol/L cacodylate solution (pH 7.25), culated from the renal citrate consumption minus the
and embedded in paraffin. Sections were stained with rate of tubular citrate reabsorption. Fractional excretion
hematoxylin and eosin. The degree of cystic disease (size was calculated from the excretion rate divided by the
of cysts, interstitial widening and fibrosis, presence of filtered load. Renal ammonia production was calculated
inflammatory cells) was evaluated blindly using an arbi- from the RBF 3 (renal venous blood [ammonia] 2 arte-
trary scale of 0 to 4, where 0 represents the normal rial blood [ammonia]) plus the urinary excretion rate.
condition and 4 represents severe changes. The partial pressure of cortical tissue ammonia (PNH3)
was estimated from the renal vein total NH41 concentra-Chemical analyses
tion and arterial blood pH [16, 17] and this formula:
Polyfructosan (a synthetic inulin) in plasma and urine
PNH3 5 (total NH41 3 22.09)/(10pK 2 pH 3 a)was determined by an anthrone method [12]. PAH was
determined by Bratton and Marshall’s method [13]. Ci- where the pK for NH41 is 9.02. The pH of renal venoustrate in plasma, urine, and tissue samples was determined
and arterial blood are assumed to be the same, and the
spectrophotometrically using a citrate lyase method
solubility coefficient (a) for ammonia is 0.91 [18].
(Boehringer Mannheim, Indianapolis, IN, USA). Recov-
ery of citrate added to plasma averaged 99 6 6% (N 5 Statistical methods
11). When kidney tissue was analyzed for citrate, we
Data presented are means 6 SD. They were analyzedobserved a 100 6 5% (N 5 25) recovery of an internal
by two-way analysis of variance (ANOVA), after a pre-citrate standard at five minutes after adding the citrate
liminary test for homogeneity of variances. Individuallyase, indicating completion of the reaction. The absor-
groups were compared with the Bonferroni method. Ifbance readings, however, continued to drift appreciably
variances were heterogeneous, the Kruskal–Wallis testwith time, probably because of the presence of nicotin-
and Dunn’s test were used to compare means. A P valueamide adenine dinucleotide (NADH) oxidase activity in
of less than 0.05 was considered significant.kidney cortex extracts. To correct for this “creep,” we
measured absorbance every 5 minutes for a total of 20
minutes after adding the citrate lyase and extrapolated RESULTS
the absorbance back to time zero [14]. Ammonia was
Overall function in six-month-old ratsdetermined using a glutamate dehydrogenase-based kit
The effects of KCitr consumption in six-month-old(Boehringer Mannheim). Recovery of ammonia added
normal rats and rats with PKD are summarized in Tableto plasma averaged 100 6 1.4% (N 5 4). Phosphate in
1. The most remarkable finding is that GFR was com-plasma was determined by the Fiske-SubbaRow method.
pletely normal in rats with PKD that had been treatedPotassium in urine and plasma and calcium in plasma,
with KCitr, whereas GFR was only 37% of normal inurine, and kidney tissue were determined using an atomic
rats with PKD that had consumed tap water. RBF alsoabsorption spectrophotometer (model 951; Instrumenta-
was normal in the rats with PKD that had been treatedtion Laboratory, Wilmington, MA, USA). Tissue sam-
with KCitr and was about half of normal in untreatedples were homogenized in a solution containing 4% (vol/
rats with PKD. KCitr treatment had no effect on bodyvol) butanol, 0.2 mol/L HCl, and 36 mmol/L LaCl3 [15]
weight or blood pressure, in agreement with our earlierusing a Polytron homogenizer (Brinkmann Instruments,
findings at three months of age [7].Westbury, NY, USA). Recovery of calcium added to
A comparison of water-drinking normal rats and wa-tissue samples averaged 103 6 3% (N 5 9). Samples
ter-drinking rats with PKD (Table 1) shows that theand standards were always prepared in the same matrix
solutions. animals with cystic disease had heavier kidneys, higher
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Table 1. Effects of KCitr consumption on function in six-month-old normal rats and rats with PKD
Normal rats Rats with PKD
Tap water KCitr Tap water KCitr
Body weight g 464628 (14) 446625 (13) 462629 (13) 464610 (12)
Kidney weight g 1.5560.14 (14) 1.5960.15 (13) 2.6460.40 (13)c 2.8360.28 (12)e
Kidney cortex % H2O 78.960.4 (10) 80.260.6 (9)c 87.560.6 (9)c 84.460.5 (7)e,g
Kidney medulla % H2O 83.060.6 (10) 84.060.6 (9)b 85.060.7 (9)c 83.960.5 (7)f
MABP mm Hg 10766 (14) 10667 (13) 116610 (13)a 11966 (12)e
Hematocrit % cells 4761 (14) 4461 (13)a 3964 (13)b 4361 (12)
GFR lL/min per 100 g body weight 392631 (14) 448643 (13)a 146667 (13)c 418637 (12)g
V˙ lL/min per 100 g body weight 6.861.7 (14) 6.761.7 (13) 8.463.6 (13) 9.362.4 (12)d
PAH extraction 0.8860.02 (14) 0.8460.04 (13) 0.3760.17 (13)b 0.7260.05 (12)
Renal blood flow mL/min 18.562.5 (14) 18.562.3 (13) 9.762.3 (13)c 17.061.4 (12)g
Values are means 6 SD (number of rats). Kidney data are for the left kidney. Abbreviations are: PKD, polycystic kidney disease; KCitr, potassium citrate/citric
acid solution; MABP, mean arterial BP; V˙, urine flow rate.
aP , 0.05, bP , 0.01, and cP , 0.001 compared with normal rats on tap water
dP , 0.05 and eP , 0.001 compared with normal rats on KCitr
fP , 0.01 and gP , 0.001 compared with rats with PKD on tap water
kidney water contents, higher blood pressure, lower he- Renal citrate, ammonia, and electrolyte handling in
six-month-old ratsmatocrit, and lower PAH extraction. The increased kid-
ney size and water content reflect cyst fluid accumulation. Acid-base measurements are presented in Table 2.
KCitr treatment did not prevent overall renal enlarge- Rats with PKD that drank tap water showed evidence
ment in rats with PKD (Table 1). The histology of cystic of a metabolic acidosis (average plasma pH of 7.30 and
bicarbonate concentration of 19 mEq/L). KCitr treat-kidneys in untreated and treated rats was, however, quite
ment increased blood pH and plasma bicarbonate con-different (Fig. 1). In tap water-drinking rats with PKD,
centration in the rats with PKD, but did not significantlythere was severe cystic disease, with numerous large cysts,
affect these variables in normal rats. KCitr treatmentinterstitial widening and fibrosis, and numerous inflam-
significantly increased urine pH, by about 0.5 pH unit,matory cells; the disease score averaged 4 6 0 (N 5 7).
in both normal rats and rats with PKD.In KCitr-treated rats with PKD, the disease score aver-
Data on renal citrate handling in normal rats and inaged 2.6 6 0.4 (N 5 7), and in no case was cystic disease
rats with PKD that had consumed either tap water orjudged to be severe (a score of 4).
KCitr solution are presented in Table 3. It is notable
In the normal rats, KCitr treatment had no significant
that in the normal rats, the arterial plasma citrate concen-
effect on any of the variables measured (Table 1) or on tration and renal cortical citrate concentration were not
renal histology, except for about a 10% increase in GFR, affected by increased citrate intake. In fact, KCitr intake
a small increase in cortex and medulla water contents, in normal rats did not affect any of the parameters mea-
and a fall in hematocrit. In rats with PKD, KCitr treat- sured except for expected increases in urine citrate con-
ment overall tended to produce more normal renal func- centration, excreted citrate, and the fraction of filtered
tion and structure (Table 1 and Fig. 1). citrate excreted in the urine.
Rats with PKD that were on tap water had an elevated
Long-term survival arterial plasma citrate concentration (about twice nor-
mal), diminished citrate extraction and consumption, ele-KCitr treatment significantly prolonged the life of rats
vated urinary citrate excretion (about 10 times normal),with PKD (Fig. 2). The average survival time of rats that
and elevated renal cortical citrate concentration whendrank tap water was 288 6 39 days (N 5 18). The average
compared with normal rats on tap water (Table 3). Thesurvival time of rats with PKD on KCitr was 506 6 33
higher rate of citrate excretion in rats with PKD is notdays (N 5 6). The KCitr-treated animals lived well be-
due to a difference in urine pH [19, 20], since both groups
yond the time all of the untreated rats with PKD had that drank tap water had urine pH values about 5.9
died (Fig. 2). Histologic examination of kidneys from (Table 2). A novel finding is that cortical tissue citrate
old KCitr-treated rats with PKD demonstrated marked concentration is also elevated in rats with PKD, although
cystic changes; hence, this treatment does not stop pro- to a variable extent. Figure 3 illustrates that this variabil-
gression of the disease. Normal plasma chemistry values ity is related to the degree of renal impairment in un-
(urea, creatinine, and potassium) were found in three treated rats with PKD; tissue citrate concentration was
normal rats that had consumed KCitr solution for 20 inversely related to the GFR.
Increased citrate intake paradoxically led to a lowermonths (data not shown).
Fig. 1. Photomicrographs of hematoxylin and eosin-stained sections
of the outer cortex of representative kidneys from six-month-old (A)
normal rats on water, (B) rats with polycystic kidney disease (PKD)
on a potassium citrate (KCitr) solution, and (C) rats with PKD on
water (3100). KCitr-treated rats with PKD showed less cyst enlarge-
ment, fewer atrophied tubules, and less interstitial widening and in-
flammation.
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Fig. 2. Survival of male heterozygous rats with PKD drinking tap water
(s) or on a KCitr solution (d). The age of death is plotted as a function Fig. 3. Inverse relationship between cortical [citrate] and glomerular
of time. Treatment with KCitr starting at the age of one month led to filtration rate (GFR) in untreated rats with PKD (d). The equation of
an increase in survival time from 288 6 39 days (N 5 18) to 506 6 33 the least squares line is tissue [citrate] 5 20.00503 3 GFR 1 1.59 (r 5
days (N 5 6). 20.77, P , 0.05). Average values for eight normal rats consuming water
are shown on the right (r).
arterial plasma citrate concentration and a lower concen-
tration of citrate in cortical tissue of rats with PKD com- consumption in the normal rats, but was not affected
pared with rats with PKD that drank tap water (Table by this treatment in the rats with PKD (Table 5). No
3). Overall, KCitr treatment of rats with PKD led to a significant differences in calcium excretion were seen in
more normal pattern of renal handling of citrate. the four groups. In untreated rats, cortical tissue calcium
Measurements of renal handling of ammonia are sum- levels were higher with PKD than in normals. Potassium
marized in Table 4. KCitr treatment in normal rats led citrate treatment actually raised the tissue calcium levels
to significant decreases in renal ammonia production and in the cortex and medulla of normal rats and in the
excretion. This may be due to two effects: (1) oxidation medulla of rats with PKD. Plasma phosphate concentra-
of citrate to bicarbonate and its consequent alkalinizing tion was elevated in the rats with PKD on water, but
effect, and (2) inhibition of ammoniagenesis by citrate was brought closer to normal in the rats with PKD that
[21]. Rats with PKD on tap water had lower rates of had been treated with KCitr. These changes in plasma
production and excretion of ammonia than did normal phosphate level most likely reflect retention of phos-
rats on tap water. KCitr-treated rats with PKD had the phate in animals with severe renal disease (untreated
same rates of production and excretion of ammonia as
rats with PKD) and adequate phosphate disposal in ani-
normal KCitr-treated rats.
mals with a normal GFR (KCitr-treated rats with PKD).
Arterial ammonia concentration was lower in the rats
with PKD than in normal rats when both drank tap Effects of varying drinking fluid composition
water. Otherwise, there were no statistically significant
Effects of varying the composition of the drinkingdifferences in arterial ammonia concentration, renal ve-
solutions were determined in clearance studies on three-nous ammonia concentration, or cortical PNH3 among the
month-old rats. Figure 4 shows the measurements of leftfour groups (Table 4).
kidney GFR from these new experiments along withData on electrolyte handling in normal rats and in rats
results from our previous study on the effects of intakewith PKD that drank tap water or KCitr solution are
of tap water or KCitr solution [7]. The data are normal-shown in Table 5. Surprisingly, the plasma potassium con-
ized per 100 g body weight. None of the treatments hadcentration was significantly decreased in both normal rats
a significant effect on body weight, and none preventedand in rats with PKD that consumed KCitr when com-
renal enlargement in rats with PKD (data not shown).pared with water-drinking rats. Urinary potassium excre-
The intake of an ammonium citrate/citric acid solutiontion was elevated with KCitr intake, as expected. The
had no beneficial effect on GFR in rats with PKD; GFRfractional excretion of potassium (FEK) was increased
averaged 261 6 22 mL/min-100 g body weight, about halfwith potassium intake in normal rats; in the rats with
of normal, and was the same as in water-drinking ratsPKD treated with KCitr, FEK was below that observed
of the same age (Fig. 4). Urine pH in rats consumingin untreated rats, most likely because of the higher GFR
ammonium citrate/citric acid solution was 5.77 6 0.04and filtered potassium load in the KCitr-treated rats.
Plasma calcium was significantly decreased by KCitr (N 5 4) in normal rats and 5.60 6 0.09 (N 5 4) in rats
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Table 2. Acid-base measurements in six-month-old normal rats and rats with PKD
Normal rats Rats with PKD
Tap water KCitr Tap water KCitr
(N 5 14) (N 5 13) (N 5 13) (N 5 12)
Arterial pH 7.3860.03 7.3960.06 7.3060.05b 7.3960.04d
Arterial PCO2 mm Hg 3764 4066 3965 3764
Arterial plasma [HCO32] mEq/L 2262.5 2462.1 1961.9a 2262.5c
Urine pH 5.9660.22 6.4360.25b 5.8960.22 6.3960.24d
Values are means 6 SD.
aP , 0.01 and bP , 0.001 compared with normal rats on tap water
cP , 0.01 and dP , 0.001 compared with rats with PKD on tap water
Table 3. Renal citrate handling in six-month-old normal rats and rats with PKD
Normal rats Rats with PKD
Tap water KCitr Tap water KCitr
(N 5 9) (N 5 8) (N 5 8) (N 5 7)
Arterial [citrate] mmol/L 0.08660.018 0.08160.013 0.15460.038c 0.07760.015g
Citrate extraction 0.3460.08 0.3360.10 0.2160.08b 0.3360.09
Urine [citrate] mmol/L 0.0860.06 0.7060.54c 0.6560.33c 1.0460.57
Filtered citrate nmol/min 149631 158637 107618b 161639f
Excreted citrate nmol/min 2.362.1 13.468.6c 25.4616.9c 43.6620.3d
Reabsorbed citrate nmol/min 146630 145637 82617c 117624
FEcitrate % 1.461.0 8.865.7c 23.0612.8c 26.366.7e
Citrate consumption nmol/min 257666 2676137 141657b 202668
Peritubular citrate uptake nmol/min 110662 1226108 59641 85673
Cortical [citrate] mmol/kg wet weight a 0.26960.104 0.26460.069 0.82560.516c 0.27160.071g
Values are means 6 SD. Kidney data are for the left kidney.
a Measurements in the four groups were done in 8, 7, 9, and 7 rats, respectively
bP , 0.05 and cP , 0.001 compared with normal rats on tap water
dP , 0.01 and eP , 0.001 compared with normal rats on KCitr
fP , 0.05 and gP , 0.001 compared with rats with PKD on tap water
with PKD; intake of this solution was associated with an month of age, results in normal GFR and renal blood
acidic urine pH. flow in six-month-old animals (Table 1). These results
By contrast, substitution of sodium for potassium in extend our previous study in which a beneficial effect of
the drinking solution yielded results similar to KCitr. KCitr treatment was seen in rats treated from one to
GFR in the rats with PKD, 532 6 96 mL/min-100 g body three months of age [7]. Long-term KCitr therapy, started
weight, was normal. Urine pH averaged 6.57 6 0.23 (N 5 at the age of one month, prolongs the survival time of rats
4) in normal rats and 6.51 6 0.33 (N 5 4) in rats with with PKD (Fig. 2). We do not know whether initiation of
PKD. The renal histology of rats with PKD that had treatment at an older age, when some degree of renal
consumed the sodium citrate salt (data not shown) was impairment is already present, would also be effective
identical to that seen in rats of the same age that had in slowing the progression of PKD.
consumed KCitr [7]. These results clearly indicate that
Renal handling of citrateit is the intake of citrate or citric acid, not the provision
of extra potassium in the diet, that is responsible for the We studied renal handling of citrate in an attempt to
beneficial effect of KCitr. understand why it was effective. Some of our results
With the administration of K3 citrate (potassium ci- were not expected (1) citrate concentrations in plasma,
trate but no citric acid), GFR was maintained as with renal cortical tissue, and urine were all higher than nor-
KCitr. Urine pH in the rats on K3 citrate solution was mal in untreated rats with PKD; and (2) KCitr treatment
6.08 6 0.25 (N 5 2) in normal rats and 5.83 6 0.35 (N 5 of rats with PKD led to decreases in plasma and tissue
5) in rats with PKD. Overall, the results demonstrate citrate levels, probably as a consequence of more normal
that alkalinizing citrate salts prevent a decline in GFR renal function.
in rats with PKD.
Plasma citrate. Two factors may explain the elevated
arterial plasma citrate concentration in untreated rats
DISCUSSION with PKD (Table 3). First, renal consumption of citrate
was decreased. The kidneys are the major site of citrateThis study demonstrates that chronic treatment of rats
which have PKD with a KCitr solution, starting at one utilization in the body [22]. Second, rats or patients with
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Table 4. Ammonia handling in six-month-old normal rats and rats with PKD
Normal rats Rats with PKD
Tap water KCitr Tap water KCitr
(N 5 5) (N 5 5) (N 5 5) (N 5 5)
Arterial ammonia lmol/L 4066 37 63 3264a 3564
Renal vein ammonia lmol/L 84611 7766 79619 84617
Cortical PNH3 mm Hg 3 10
26 4766 53615 3369 48612
Ammonia excretion lmol/min 0.7460.12 0.4060.09b 0.2860.19c 0.3260.07
Ammonia production lmol/min 1.6760.23 1.1060.26a 0.7760.41c 1.1460.32
Values are means 6 SD.
aP , 0.05, bP , 0.01, and cP , 0.001 compared with normal rats on tap water
Table 5. Electrolyte handling in six-month-old normal rats and rats with PKD
Normal rats Rats with PKD
Tap water KCitr Tap water KCitr
Plasma [K1] mEq/L 3.7060.30 (9) 2.9160.45 (8)b 4.0460.56 (8) 3.3460.17 (7)d
Excreted K1 lEq/min 1.5960.16 (9) 2.9560.48 (8)c 1.7860.28 (8) 3.1660.29 (7)f
FEK % 2664 (9) 5166 (8)c 64616 (8)c 4768 (7)d
Plasma [calcium] mg/100 mL 8.6060.24 (6) 8.0160.37 (4)a 8.6460.24 (3) 8.4760.33 (4)
Excreted calcium lg/min 0.6260.32 (9) 0.3660.12 (6) 1.1060.59 (6) 0.7460.26 (8)
Cortex [calcium] mg/kg wet weight 9564 (6) 176689 (3)a 15368 (3)a 181628 (3)
Medulla [calcium] mg/kg wet weight 156621 (6) 8556677 (3)c 222637 (3) 10016462 (3)e
Plasma [phosphate] mg/100 mL 4.9760.34 (10) 5.3760.67 (9) 8.7061.45 (9)c 6.0460.61 (7)f
Values are means 6 SD (number of animals). Kidney data are for the left kidney.
aP , 0.05, bP , 0.01, and cP , 0.001 compared with normal rats on tap water
dP , 0.05, eP , 0.01 and fP , 0.001 compared with rats with PKD on tap water
renal failure develop secondary hyperparathyroidism, and PKD may provide an explanation for increased citrate
excretion. A high level of citrate in proximal tubule cellsparathyroid hormone promotes release of citrate from
bone and elevates the plasma citrate concentration [11]. would diminish the driving force for reabsorption of fil-
tered citrate across the luminal cell membrane and inIn normal rats, plasma citrate was not affected by the
level of chronic intake (Table 3). Likewise, patients on this way could lead to increased citrate excretion [20].
Although the tenfold higher rate of citrate excretionlong-term intake of potassium citrate do not show an
increase in serum citrate concentration [23]. in rats with PKD compared with normal rats is most
impressive (Table 3), it is important to note that onlyTissue citrate. The elevated renal cortical tissue citrate
levels in untreated rats with PKD (Table 3 and Fig. 3) 1% of the filtered load is excreted by the normal rat
kidney. Fractional excretion of citrate in the untreatedcould be due to both an increase in intracellular citrate
concentration and/or an increase in the tubular fluid or rat with PKD, 23% (Table 3), is similar to fractional
excretion of citrate in the normal human kidney, abouturine citrate level. It appears to be mainly due to an
increase in intracellular level, since urine concentrations 10 to 35% [20]. Excessive urinary excretion of citrate in
the rat with PKD may contribute to the development ofof citrate were elevated in the KCitr-treated rats and yet
tissue citrate levels were not increased in these animals metabolic acidosis, since loss of citrate represents a loss
of potential bicarbonate.(Table 3).
Many factors can influence renal tissue citrate levels, Citrate consumption. Citrate is an important meta-
bolic substrate in the kidneys, accounting for about 10%including intracellular pH, citrate production or con-
sumption, or altered citrate transport by luminal and of their energy production [22, 24, 25]. In untreated rats
with PKD, renal citrate consumption was lower thanperitubular cell membrane carriers [20]. Although we
cannot say why the tissue citrate level was increased in normal (Table 3). Decreased GFR and consequent de-
creased tubular sodium reabsorption in cystic kidneysrats with PKD, the finding of Ogborn et al that tissue
succinate levels are low suggests impaired mitochondrial probably contributes to the decreased citrate consump-
tion, although we cannot rule out an intrinsic defect inmetabolism of citrate [8].
Citrate reabsorption and excretion. High urine citrate citrate utilization.
Citrate and PKD. Citrate handling by cystic kidneysconcentration and elevated citrate excretion in rats with
PKD was first reported by Ogborn et al [8]. Our finding is clearly abnormal. It is still not obvious, however, why
citrate treatment is beneficial. Had we known beforethat renal cortical tissue citrate is elevated in rats with
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Fig. 4. Summary of effects of various treat-
ments on GFR in three-month-old normal rats
(h) and rats with PKD ( ). The data from
the rats treated with KCitr or tap water are
from our previous study [7]. GFR was pre-
served in the rats with PKD, which consumed
solutions of KCitr (K3 citrate 1 citric acid),
Na3 citrate 1 citric acid, or K3 citrate alone,
but was about half of normal in the rats that
drank tap water or the (NH4)2 citrate 1 citric
acid solution.
undertaking these experiments that plasma and kidney Calcium and citrate
cortex citrate concentrations are elevated in untreated We hypothesized that citrate administration might ex-
rats with PKD, we might have been dissuaded from ad- ert its beneficial effect by preventing precipitation of
ministering additional citrate. These surprising results bol- calcium salts and lowering tissue calcium levels. We
ster our conclusion (discussed later in this article) that found, however, that KCitr treatment for five months
the alkalinizing effect of citrate, rather than some other led to higher levels of calcium in the kidney, even in
attribute of citrate, underlies the success of citrate therapy. normal rats (Table 5). Accumulation of calcium in the
Data on citrate handling in patients with PKD are rat kidney with citrate intake has been observed before
limited. In one study of PKD patients with nephrolithia- [31] and appears to be a consequence of the elevated
sis, an abnormally low rate of citrate excretion was seen urine pH. Deposition of calcium salts in kidney tissue
in 67% of the patients, but this could be due an abnor- occurs in rats [2] and patients [26] with PKD, and can
mally low urine pH [26]. Renal citrate handling by PKD lead to tissue damage and ischemia. In our study, treat-
patients, as far as we know, has not been systematically ment with KCitr produced only a modest nephrocal-
studied. cinosis that did not appear to progress; normal rats on
KCitr for 20 months had tissue calcium levels the sameRenal handling of ammonia
as in six-month-old rats (data not shown). Nevertheless,
The suggestion has been made that increased intrare-
the modest elevation in tissue calcium suggests thatnal levels of ammonia might contribute to tubulointersti-
KCitr does not ameliorate PKD by lowering tissue cal-tial injury in chronic renal diseases [27, 28], including
cium levels.PKD [9, 10, 29]. Torres et al reported an elevated ammo-
Citrate complexes calcium in the urine and inhibitsnia level in human cyst fluid, but whether the fluid was
the formation of renal stones [23]. Torres et al foundderived from proximal or distal cysts is not clear [10].
that giving high concentrations of another alkalinizingAlso, cyst fluid total ammonia levels may not reflect
agent, potassium bicarbonate (200 to 300 mmol/L), causedinterstitial ammonia levels, since fluid within tubules or
extensive precipitation of calcium phosphate in medul-cysts is generally more acidic and ammonia is trapped
lary collecting ducts [9]. Citrate may be a safer compoundas NH41. In the present study, we detected no increase
to administer than other agents that alkalinize the urine.in arterial or renal vein total ammonia concentrations
or in cortical tissue PNH3 in rats with PKD (Table 4). Alkalinizing effect of citrateTherefore, our data do not support the hypothesis that
Data in the present study strongly suggest that theelevated intrarenal ammonia levels are responsible for
beneficial effect of treatment with KCitr is a consequencekidney damage in this disease.
of the citrate ion and its oxidation in the body to bicar-Urinary ammonia production and excretion were be-
bonate (alkalinizing effect). Several observations con-low normal in cystic rat kidneys. Preuss et al demon-
firm an alkalinizing effect of citrate. In rats with PKD,strated earlier that ammonia excretion was reduced in
KCitr administration resulted in an arterial blood pH ofpatients with PKD and postulated that this was second-
7.39, compared with 7.30 in water-drinking rats (Tableary to decreased renal ammonia production, as we found
2). Urine pH was significantly more alkaline after thein the rat with PKD (Table 4) [30]. Impaired urinary
administration of KCitr in both normal rats and ratsexcretion of ammonia could contribute to the metabolic
acidosis in untreated rats with PKD (Table 2). with PKD (Table 2). Renal ammonia synthesis, which is
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intake in normal rats (Table 4). tometer, and Dr. Wiltz Wagner and Joseph Bailey for use of their
The ion-substitution experiments demonstrated that blood gas analyzers.
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is not the explanation for preservation of GFR, because Drive, Indianapolis, Indiana, USA.
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(Fig. 4). If unmetabolized citrate or citric acid were key,
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